ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMM Immupharma Plc

2.21
0.03 (1.38%)
Last Updated: 14:08:31
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 1.38% 2.21 2.20 2.25 2.25 2.20 2.20 1,190,181 14:08:31
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.97 7.5M

Immupharma PLC Appointment of Joint Brokers (1740B)

19/09/2018 7:01am

UK Regulatory


Immupharma (LSE:IMM)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Immupharma Charts.

TIDMIMM

RNS Number : 1740B

Immupharma PLC

19 September 2018

19 September 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

Appointment of Joint Brokers

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company's NOMAD and broker.

Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma said:

"As per our recently announced corporate update, we are looking forward with confidence to the future progress of ImmuPharma. As part of our continued proactive investor relations strategy, we also look forward to working with Stanford Capital and SI Capital as part of our corporate advisory team."

 
 For further information please contact: 
                                                        + 44 (0) 20 
   ImmuPharma plc (www.immupharma.co.uk)                 7152 4080 
   Tim McCarthy, Chairman 
                                                        + 44 (0) 7721 
   Lisa Baderoon, Head of Investor Relations             413496 
   Northland Capital Partners Limited (NOMAD & Joint    +44 (0)20 3861 
    Broker)                                              6625 
    David Hignell, Dugald Carlean, Jamie Spotswood, 
    Corporate Finance 
    Rob Rees, Corporate Broking 
 
    Stanford Capital Partners (Joint Broker)             +44 (0) 20 
    Patrick Claridge                                     3815 8880 
    Chris Coleman 
 
    SI Capital (Joint Broker)                            +44 (0) 1483 
    Nick Emerson                                         413500 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPFKFDDABKDQCD

(END) Dow Jones Newswires

September 19, 2018 02:01 ET (06:01 GMT)

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Your Recent History

Delayed Upgrade Clock